Combigene

Contact

Jan Nilsson

Chief Executive Officer
jan.nilsson@combigene.com
Tel: +46 46 275 6010
Medicon Village
SE-223 81 Lund
Visiting address: Scheelevägen 2

Karin Agerman, Phd

Chief Research and Development Officer

karin.agerman@combigene.com
Tel: +46 73 941 90 10
Medicon Village
SE-223 81 Lund
Besöksadress: Scheelevägen 2

Jan Nilsson

Chief Executive Officer
jan.nilsson@combigene.com
Tel: +46 46 275 6010
Medicon Village
SE-223 81 Lund
Visiting address: Scheelevägen 2

Karin Agerman, Phd

Chief Research and Development Officer

karin.agerman@combigene.com
Tel: +46 73 941 90 10
Medicon Village
SE-223 81 Lund
Besöksadress: Scheelevägen 2

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook